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Abstract
Background: The Ecballium elaterium trypsin inhibitor (EETI-II), a 28-amino acid member of the knottin family of peptides,
contains three interwoven disulfide bonds that form multiple solvent-exposed loops. Previously, the trypsin binding loop of
EETI-II has been engineered to confer binding to several alternative molecular targets. Here, EETI-II was further explored as a
molecular scaffold for polypeptide engineering by evaluating the ability to mutate two of its structurally adjacent loops.
Methodology/Principal Findings: Yeast surface display was used to engineer an EETI-II mutant containing two separate
integrin binding epitopes. The resulting knottin peptide was comprised of 38 amino acids, and contained 11- and 10-
residue loops compared to wild-type EETI-II, which naturally contains 6- and 5-residue loops, respectively. This knottin
peptide bound to avb3 and avb5 integrins with affinities in the low nanomolar range, but bound weakly to the related
integrins a5b1 and aiibb3. In addition, the engineered knottin peptide inhibited tumor cell adhesion to vitronectin, an
extracellular matrix protein that binds to avb3 and avb5 integrins. A
64Cu radiolabeled version of this knottin peptide
demonstrated moderate serum stability and excellent tumor-to-muscle and tumor-to-blood ratios by positron emission
tomography imaging in human tumor xenograft models. Tumor uptake was ,3–5% injected dose per gram (%ID/g) at one
hour post injection, with rapid clearance of probe through the kidneys.
Conclusions/Significance: We demonstrated that multiple loops of EETI-II can be mutated to bind with high affinity to
tumor-associated integrin receptors. The resulting knottin peptide contained 21 (.50%) non-native amino acids within two
mutated loops, indicating that extended loop lengths and sequence diversity were well tolerated within the EETI-II scaffold.
A radiolabeled version of this knottin peptide showed promise for non-invasive imaging of integrin expression in living
subjects. However, reduced serum and metabolic stability were observed compared to an engineered integrin-binding EETI-
II knottin peptide containing only one mutated loop.
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Introduction
Cystine-knot miniproteins, also known as knottins, are small
polypeptides (20–60 amino acids) that have an interwoven
disulfide-bonded framework, triple-stranded b-sheet fold, and
possess one or more solvent exposed loops that mediate binding to
diverse targets [1,2]. Knottin family members, which include
toxins, antimicrobials, ion channel inhibitors, and protease
inhibitors, share little sequence homology apart from their core
cysteine residues [3–5]. As a result, binding epitopes have been
introduced into knottin peptides to impart them with new
molecular recognition properties without abolishing their three-
dimensional fold [6–12]. The Ecballium elaterium trypsin inhibitor
(EETI-II) knottin contains three disulfide bonds and binds to and
inhibits trypsin through a single 6-amino acid loop [13,14]. In
pivotal studies, EETI-II was used as a molecular scaffold by
rationally substituting this trypsin binding loop (PRILMR) with
grafted biologically-active peptides against targets such as elastase,
thrombopoietin, and integrins [7,9,10].
Integrins are a family of a/b heterodimeric adhesion receptors
that have distinct ligand binding specificities and cell signaling
properties [15]. Non-invasive molecular imaging agents that target
tumor-related integrin receptors will play an important role in
earlier cancer detection, disease staging, and management [16,17].
We recently used yeast surface display, a combinatorial method, to
identify EETI-II-based knottin peptides that bound with high (low
nM) affinity to avb3/avb5 or avb3/avb5/a5b1 integrins [8], which
are overexpressed on tumors or their neovasculature and mediate
angiogenesis and metastasis [18–21]. In mouse tumor models,
radiolabeled versions of these integrin-binding knottin peptides
exhibited high tumor uptake with low background in non-target
tissue (i.e. liver and kidney) [22,23].
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the EETI-II trypsin binding loop (Loop 1), additional work by our
group demonstrated high tolerance of length and sequence
diversity in other EETI-II loops [24]. In particular, a loop
containing the sequence GPNGF (Loop 3) accommodated broad
sequence diversity and tolerated a wide range of loop lengths
beyond its original 5 amino acids. In the current study, our goal
was to further explore the utility of knottins as molecular scaffolds
for polypeptide engineering by evaluating the ability to mutate two
structurally-adjacent loops within EETI-II. We used yeast surface
display to engineer an EETI-II-based knottin peptide that contains
an 11-amino acid sequence in place of Loop 1, and a 10-amino
sequence in place of Loop 3. As a model system, each engineered
loop contained a separate Arg-Gly-Asp (RGD) integrin-binding
motif [25], whose flanking residues were optimized to bind with
high affinity to tumor-associated integrin receptors. We measured
the binding affinity and specificity of this engineered knottin
peptide against cell lines expressing particular integrin receptors.
In addition, we radiolabled this knottin peptide and evaluated its
ability to target tumors in mouse xenograft models. Importantly,
we demonstrated that multiple loops of a knottin peptide,
comprising 21 non-native amino acid residues, can be engineered
to bind with high affinity to integrin receptors, and the resultant
peptide can be used as a probe for non-invasive molecular imaging
applications. These findings expand the potential of the cystine-
knot scaffold for future studies where multiple knottin loops can be
simultaneously engineered to bind to exogenous targets. Such
capability will be important, for example, in engineering binders
against molecular targets which require an increased surface area
to achieve high affinity interactions.
Results
Engineering Knottin Peptides Containing Two Separate
Integrin Binding Loops
Previously, we used yeast surface display to engineer a high
affinity integrin binding sequence into Loop 1 of EETI-II
(Figure 1A, magenta) [8]. This mutant was termed EETI-II
2.5D. In the current study, our goal was to explore the potential to
introduce an additional, but distinct, integrin-binding epitope
within a structurally-adjacent knottin loop. EETI-II Loop 3
(Figure 1A, cyan) was chosen as our previous work suggested that
this loop was more amenable to mutation compared to Loop 2
[24]. First, we scrambled the RGD sequence in EETI-II 2.5D
(PQGRDGWAPTS), abolishing its function, so that we could
evolve a separate integrin binding epitope within Loop 3. Second,
combinatorial libraries were created in which EETI-II Loop 3
(sequence GPNGF) was substituted with XXXRGDXXX, XX-
XRGDXXXX, and XXXRGDXXXXX, where X can be any
amino acid (Figure 1B and Table S1). These loop libraries of 9, 10,
and 11 amino acids were chosen based on our experience with
engineering optimized integrin-binding knottin peptides [8,11,12].
EETI-II mutants were displayed on the surface of yeast as fusions
to the agglutinin mating proteins under the control of a galactose
promoter, and contained a C-terminal cMyc epitope tag for
detection and quantification of knottin expression levels using an
anti-cMyc antibody. The yeast-displayed EETI-II libraries were
pooled, and were screened using high-throughput fluorescent-
activated cell sorting (FACS) to isolate mutants that were well-
expressed on the yeast cell surface and bound with high affinity to
detergent-solubilized avb3 integrin. The initial library contained a
small fraction of clones that bound to 100 nM avb3 integrin
(Figure 1C), demonstrating that specific RGD flanking sequences
are critical for high affinity integrin binding. Integrin-binding yeast
were isolated, cultured, and induced for knottin expression, and
the sorting process with avb3 integrin was repeated. Nine rounds of
FACS were used to isolate mutants that bound with high affinity to
avb3 integrin (Table S2). In later sort rounds the integrin
concentration was lowered to 2 nM, and a diagonal sort gate
was used to isolate clones that bound the highest levels of avb3
integrin for a given level of yeast expression (Figure 1C). A
predominant clone, 3-4C (Loop 1: PQGRDGWAPTS,
Loop 3: REARGDMPRT), was isolated in the final round of
sorting after conducting an ‘‘off-rate’’ screen by incubating the
Figure 1. Summary of knottin engineering. (A) Three dimensional structure of wild-type EETI-II (pbd: 2it7, ref [13]) showing Loop 1, previously
engineered for high affinity avb3 integrin binding (magenta), Loop 2 (dark blue), and Loop 3 (cyan). Cysteines I to VI are labeled and shown in yellow.
(B) Strategy for knottin engineering. The primary sequences of wild-type EETI-II and mutant 2.5D are shown with disulfide connectivities indicated in
yellow. The RGD motif in Loop 1 was scrambled to RDG and three different Loop 3 libraries were created and screened for high affinity to avb3
integrin. After nine rounds of library screening by FACS the predominant mutant, knottin 3-4C, is shown. Three different variants 3-4A: (RGD/RGD), 3-
4B: (RGD/RDG), and 3-4C: (RDG/RGD) were synthesized and folded. (C) FACS density dot plots showing the library sort progression for enrichment of
improved avb3 integrin binders. R denotes the sort round, and the concentration of avb3 integrin is indicated. Actual sort gates are shown as
polygons in the upper right quadrant.
doi:10.1371/journal.pone.0016112.g001
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step in the presence of soluble EETI-II 2.5D competitor. We
synthesized three permutations of this knottin peptide consisting of
one or two functional integrin binding loops: 1) 3-4A (Loop 1:
RGD/Loop 3: RGD), 2) 3-4B (Loop 1: RGD/Loop 3: RDG), and
3) 3-4C (Loop 1: RDG/Loop 3: RGD) (Figure 1B). These knottin
peptides were folded and purified as previously described [8], and
their masses were confirmed by matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) mass spectrometry (Figure
S1 and Table S3).
Binding of Engineered Knottin Peptides to U87MG
Glioblastoma Cells
The engineered knottin peptides were tested for their ability to
compete with
125I-echistatin for binding to integrin receptors
expressed on U87MG glioblastoma cells, which express ,10
5 avb3
integrin receptors per cell [26]. Echistatin, a polypeptide found in
snake venom, binds to multiple integrin receptors with high
affinity [8,27] and was used as a positive control. The knottin
peptide 3-4C (RDG/RGD) bound to U87MG cells with an IC50
value of 1563 nM (Figure 2 and Table 1). In comparison, the
knottin peptides 3-4A (RGD/RGD) and 3-4B (RGD/RDG)
bound to U87MG cells with IC50 values of 562 nM and
6868 nM, respectively, relative to echistatin, which bound with
an IC50 value of 4.960.1 nM (Figure 2 and Table 1). EETI-II
2.5D (Figure 1B), which was used as a starting point for the current
knottin engineering study, was previously found to have an IC50 of
1966 nM [8]. Mutant 3-4B (RGD/RDG) exhibited a ,3.5-fold
decrease in binding compared to EETI-II 2.5D, most likely due to
conformational perturbations that result when Loop 3 is mutated
from 5 to 10 amino acids. However, these substantial changes in
the length and composition of Loop 3 do not abolish the ability of
Loop 1, which contains the sequence PQGRDGWAPTS from
EETI-II 2.5D, to bind to integrins with high affinity. In addition,
the weaker binding affinity observed with mutant 3-4B (RGD/
RDG) compared to 3-4A (RGD/RGD) highlights the interdepen-
dence of the loops in integrin binding, while the similarities in
binding affinity of mutant 3-4A (RGD/RGD) and 3-4C (RDG/
RGD) suggests that the newly engineered Loop 3 contributes to
the majority of the binding.
Integrin-Binding Specificity of Engineered Knottin
Peptides
U87MG cells have been shown to express several different
integrin receptor subtypes, including avb3, avb5, and a5b1 [28].
Therefore, to probe the integrin binding specificity of the
engineered knottin peptides, competition binding assays were
performed with
125I-echistatin and K562 leukemia cells, which
naturally express a5b1 integrin, or K562 cells that have been stably
transfected to express avb3, avb5,o raiibb3 integrin receptors [29].
Echistatin, which has been previously shown to bind to avb3, avb5,
a5b1, and aiibb3 integrins [8,27], was used as a positive control,
and bound strongly to all cell types tested (Figure S2). Engineered
knottin peptides 3-4A (RGD/RGD) and 3-4C (RDG/RGD)
bound with weak affinity to untransfected K562 cells expressing
a5b1 integrin, with IC50 values of 5006200 nM and
7006200 nM, respectively (Figure S2A and Table 1). In contrast,
knottin peptides showed increased binding affinity to K562 cells
expressing avb3 or avb5 integrins, with IC50 values approaching
that of echistatin (Figure S2B-C and Table 1). Finally, we
determined that the engineered knottin peptides 3-4A and 3-4C
bound weakly to K562 cells expressing aiibb3 integrin, with IC50
values of 3006100 nM and 4006100 nM, respectively (Figure
S2D and Table 1). These IC50 values are similar to those obtained
for untransfected K562 cells expressing a5b1 integrin, but are two
orders of magnitude weaker than binding to K562 cells expressing
avb3 or avb5 integrins.
Engineered Knottin Peptides Inhibit Tumor Cell Adhesion
to Vitronectin
The ability to block tumor cells from adhering to extracellular
matrix proteins is important for treatment strategies designed to
inhibit angiogenesis and metastasis. Thus, we measured the ability
of engineered knottin peptides to block U87MG cell adhesion to
vitronectin- and fibronectin-coated microtiter plates. Vitronectin is
a natural ligand for several integrins, including avb3 and avb5,
while the a5b1 integrin receptor is selective for fibronectin [15,30].
The engineered knottin peptides strongly inhibited U87MG cell
adhesion to vitronectin in a dose-dependent manner with IC50
values in the low nM range (Figure 3A and Table 1), reflecting
their binding affinity to avb3 and avb5 integrins. In contrast, the
engineered knottin peptides only weakly inhibited U87MG cell
Figure 2. Competition binding to integrin receptors expressed on U87MG cells. Varying concentrations of unlabeled knottin peptides or
DOTA-conjugated knottin 3-4A were incubated with
125I-echistatin and allowed to compete for binding to integrin receptors expressed on the
surface of U87MG cells. Percent of
125I-echistatin bound to the cell surface is plotted versus the concentration of unlabeled knottin (A) 3-4A (X), 3-4B
(m), 3-4C (&), or (B) DOTA-knottin 3-4A (.) and unlabeled knottin 3-4A (X). Echistatin (N) was used as a positive control to compare binding data
from different experiments. The binding curves for the knottin peptides did not reach full inhibition because
125I-echistatin binds with broad
specificity to multiple integrins expressed on U87MG cells. Data shown are the average of triplicate values and error bars represent standard
deviations. IC50 values are summarized in Table 1.
doi:10.1371/journal.pone.0016112.g002
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(Figure 3B and Table 1), reflecting their much weaker binding to
a5b1 integrin. Echistatin, which binds to a5b1, avb3, avb5, and
aiibb3 integrins, was used as a positive control and inhibited
U87MG cell adhesion to both vitronectin- and fibronectin-coated
plates in a dose-dependent manner with IC50 values in the low nM
range (Figure 3).
Synthesis and Characterization of DOTA-knottin 3-4A and
64Cu-DOTA-knottin 3-4A
The knottin peptide 3-4A was site-specifically conjugated
to 1,4,7,10-tetra-azacyclododecane-N,N’,N’’,N’’’-tetraacetic acid
(DOTA) through its N-terminal amino group using an N-
hydroxysuccimide ester DOTA derivative. The resulting DOTA-
conjugated knottin peptide was purified by reversed-phase HPLC
and characterized by MALDI-TOF-MS (Figure S1 and Table S3).
Competition binding assays were performed with U87MG cells
and
125I-echistatin as described above for the unconjugated
peptides (Figure 2B). The binding affinity of DOTA-knottin 3-
4A (IC50=861 nM) is essentially unchanged compared to the
unmodified peptide (IC50=562 nM), showing that addition of
DOTA to the N-terminus did not interfere with integrin binding.
The DOTA-knottin 3-4A peptide was radiolabeled with
64Cu, and
tumor cell binding and uptake were measured using U87MG
glioblastoma cells (Figure S3). The target specificity of
64Cu-
DOTA-knottin 3-4A was measured by blocking studies using an
unlabeled integrin binding peptide (c(RGDyK)) that binds to the
same epitope on the integrin receptor. Incubation of
64Cu-DOTA-
knottin 3-4A with an excess of unlabeled c(RGDyK), resulted in a
significant decrease in cell binding (Figure S3). Next, the serum
stability of
64Cu-DOTA-knottin 3-4A was measured after
incubation in 50% mouse serum at 37uC for up to 24 hours
(Figure 4). After incubation for 1 hour in mouse serum, the
radiolabeled peptide was ,95% intact and slowly degraded over
time to ,30% after incubation in serum for 24 hours.
MicroPET Imaging of
64Cu-DOTA-knottin 3-4A in U87MG
Xenografts
Using non-invasive microPET imaging, we evaluated tumor and
non-target tissue uptake and clearance of
64Cu-DOTA-knottin 3-
4A in mice bearing human U87MG xenografts.
64Cu-DOTA-
knottin 3-4A rapidly accumulated at the tumor to levels of
3.5160.83%ID/g after 1 h post injection and cleared at a rate of
approximately 0.07%ID/g/h, resulting in a signal of
1.9760.24%ID/g at 24 h post injection (Figure 5). Kidney uptake
ranged from 10-12%ID/g at 1 h post injection and decreased to
,3–4%ID/g after 24 h post injection. Liver uptake remained low
around ,2%ID/g throughout the imaging study. Target specificity
of
64Cu-DOTA-knottin 3-4A in mouse tumor models was
confirmed by co-injecting a 1000-fold molar excess of unlabeled
c(RGDyK), resulting in significantly reduced tumor uptake at 1 h
post injection (0.536 0.03%ID/g; p,0.05) (Figure 5).
Table 1. Summary of IC50 values from competition binding and cell adhesion assays.
Ligand Binding Assay (nM) Cell Adhesion (nM)
U87MG K562 (wt) K562(avb3) K562(avb5) K562(aiibb3) Vitronectin Fibronectin
Echistatin 4.960.1 0.760.2 561 2.060.2 5631 . 4 60.1 2165
3-4A (RGD/RGD) 5625 0 0 6200 7647 613 0 0 6100 963 .1 mM
3-4B (RGD/RDG) 6868 n/d n/d n/d n/d n/d n/d
3-4C (RDG/RGD) 15637 0 0 6200 5611 3 654 0 0 6100 1562 .1 mM
DOTA-3-4A 861 n/d n/d n/d n/d n/d n/d
Data are reported in nM unless otherwise stated. n/d indicates not determined.
doi:10.1371/journal.pone.0016112.t001
Figure 3. Inhibition of integrin-dependent tumor cell adhesion. (A) Vitronectin or (B) fibronectin coated strips were incubated with U87MG
cells for 2 h with varying concentrations of echistatin (N), knottin 3-4A (X), and knottin 3-4C (&). Adherent cells remaining after several wash steps
were quantified with crystal violet staining by absorbance at 600 nm. Values were normalized against uncoated wells and wells containing no
competing peptide. Data shown are the average of three replicates performed on different days and error bars represent standard deviations. IC50
values are summarized in Table 1.
doi:10.1371/journal.pone.0016112.g003
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64Cu-DOTA-knottin 3-4A in U87MG
Xenografts
The biodistribution of
64Cu-DOTA-knottin 3-4A was deter-
mined at 1, 4, and 24 h post injection in U87MG xenograft mice
(Figure 6). Rapid tumor uptake was observed at 1 h post injection
(3.9260.70%ID/g). By measuring radioactivity in the tumor at
24 h post injection (2.5660.40%ID/g), a radiotracer washout rate
of 0.06%ID/g/h was calculated. These data are in overall
agreement with microPET imaging data presented in Figure 5.
In addition, tumor uptake was significantly inhibited in blocking
studies where a 1000-fold molar excess of unlabeled c(RGDyK)
was co-injected with the radiotracer (0.6660.17%ID/g; p,0.05).
These data further confirm the specificity of the
64Cu-DOTA-
knottin 3-4A for integrin receptors expressed at the tumor site.
64Cu-DOTA-knottin 3-4A is cleared through the kidneys and a
low residual radioactivity remained at 24 h post injection
(2.6760.22%ID/g), demonstrating that the kidneys do not retain
high amounts of the radiotracer or its metabolic byproducts.
Biodistribution analysis showed low accumulation of radioactivity
in other non-target organs (Figure 6). Slight accumulation of
radioactivity in the liver was observed from ,1 to 2%ID/g at 1 to
24 h post injection, respectively. Tissues originating from the
thoracic region exhibited low levels of background signal, while
radioactivity measured in the lungs decreased from ,1t o
0.6%ID/g from 1 to 24 h post injection. Heart and blood
radioactivity measured ,0.3%ID/g throughout the study. Radio-
activity in the muscle tissue was also low (,0.4%ID/g). These data
indicate that
64Cu-DOTA-knottin 3-4A has promising potential
for molecular imaging of integrin expression in living subjects.
In Vivo Stability of
64Cu-DOTA-knottin 3-4A
Finally, metabolic stability of
64Cu-DOTA-knottin 3-4A in
U87MG xenograft models was evaluated at 1 h post injection
(Figure 7). Analysis of urine samples indicated that intact knottin
radiotracer is excreted through the bladder, compared to the
Figure 4. Serum stability of
64Cu-DOTA-knottin 3-4A.
64Cu-DOTA-knottin 3-4A was incubated with mouse serum for up to 24 h at 37uC.
Representative HPLC traces are shown with radioactive signal (mV) plotted as a function of time. Intact
64Cu-DOTA-knottin 3-4A (*) elutes at
approximately 15 minutes. The amount of probe remaining at 1, 4, and 24 h was quantified from the area under the entire peak to be 96%, 55%, and
30%, respectively.
doi:10.1371/journal.pone.0016112.g004
Figure 5. MicroPET imaging of U87MG tumor xenografts. (A)
Representative microPET scans (coronal images, top; transverse images,
bottom) of U87MG xenografts (n=3) after injection of
64Cu-DOTA-
knottin 3-4A alone or co-injected with a large molar excess of unlabeled
c(RGDyK) pentapeptide (1 h/block). The letters B, K, L, and T represent
bladder, kidney, liver and tumor, respectively. (B) The mean %ID/g for
tumor, liver, kidney, and muscle uptake were quantified on images
generated 1, 2, 4, and 24 h post injection. Error bars represent standard
deviations of experiments performed in three mice.
doi:10.1371/journal.pone.0016112.g005
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responsible for the majority of the radioactive signal. Breakdown
of the probe also occurs in the liver and tumor, with less than
,40% of the intact radiotracer recoverable after 1 h.
Discussion
The EETI-II miniprotein consists of at least three solvent
accessible loops that are potential regions for amino acid
substitution or randomization. Previous studies have introduced
non-native epitopes into Loop 1 [6,7,9,10] or Loop 3 [24,31] of
EETI-II to study structure/function effects or to create peptides
with new molecular recognition properties. Recent work has
shown that knottin peptides have promise as tumor-targeting
probes for diagnostic applications across several molecular
imaging modalities [22,23,32–38]. In the current study, we used
yeast surface display to engineer EETI-II mutants with integrin-
binding motifs substituted into both Loops 1 and 3, with several
goals in mind. The first was to use this model system to explore the
boundaries of significantly mutating a knottin scaffold for
polypeptide engineering applications. A second goal was to
compare this new peptide to an existing integrin-binding EETI-
II mutant [22,23], in terms of binding affinity, specificity, stability,
tumor uptake and clearance, and tissue biodistribution for non-
invasive molecular imaging applications.
Extracellular matrix proteins including vitronectin, fibronectin,
osteopontin, laminin, and others, bind to particular integrin
receptors through an RGD peptide motif [25]. The RGD
sequence is constrained within a loop structure that presents a
particular conformation and stereochemical arrangement of
residues critical for optimal integrin binding affinity and specificity
[39,40]. Hence, simple substitution of EETI-II Loop 3 with several
different loop sequences derived from the integrin-binding domain
of fibronectin resulted in knottin peptides with weak binding to
avb3 integrin (data not shown). Similarly, our initial knottin RGD-
loop libraries contained very few integrin binders, which were
enriched over multiple rounds of screening. Although library
screens were performed against avb3 integrin, the knottin peptides
exhibited high affinity binding to both avb3 and avb5 integrins,
which are often co-expressed on tumors or the tumor vasculature
[18,19], and substantially weaker binding to the structurally-
related a5b1 and/or aiibb3 integrins. Previously, to isolate knottin
peptides with specificity only to aiibb3 integrin for inhibition of
platelet aggregation, we interspersed positive sorts against aiibb3
integrin with negative sorts against avb3 integrin, otherwise the
isolated knottin peptides bound with high affinity to both integrins
[11].
Substitution of EETI-II Loop 1 (normally 6 amino acids) with
an 11-amino acid loop, and Loop 3 (normally 5 amino acids) with
a 10-amino acid loop resulted in functional, high affinity integrin
Figure 6. Biodistribution in U87MG tumor xenografts. Biodis-
tribution of
64Cu-DOTA- knottin 3-4A in U87MG xenografts (n=3) was
measured in the tumor (T), blood (Bl), heart (H), liver (Li), lungs (Lu),
muscle (M), kidneys (K), spleen (Sp), brain (Br), intestine (I), skin (Sk),
stomach (St), pancreas (P), and bone (Bo). Data are presented as the
%ID/g tissue 6 SD (n=3) after intravenous injection of ,50–100 mCi
probe at 1 h (black bars), 4 h (light grey bars), and 24 h (dark grey bars).
To measure probe specificity, mice were injected with
64Cu-DOTA-
knottin 3-4A and an excess of unlabeled competitor (c(RGDyK)), and
tissue biodistribution was measured after 1 h (1 h/block, white bars).
Error bars represent standard deviations of experiments performed in
three mice.
doi:10.1371/journal.pone.0016112.g006
Figure 7. In vivo stability of
64Cu-DOTA-knottin 3-4A. Urine samples or homogenized tumor, kidney, or liver tissue were analyzed by radio-
HPLC and gamma counting 1 h post injection. Representative HPLC traces are shown. The intact radiotracer elutes at approximately 15 minutes,
while the major hydrophilic metabolites and free copper elute with the column flow through. Only limited quantities of urine were available from the
mice, resulting in higher background noise for this sample.
doi:10.1371/journal.pone.0016112.g007
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to integrins with high affinity, as confirmed by measurements
performed with knottins containing scrambled RDG control loops.
Mutant 3-4B (RGD/RDG) exhibited decreased binding compared
to EETI-II 2.5D on U87MG cells (6868 nM versus 1966 nM),
indicating a ,3-fold drop in affinity through introduction of a 10-
amino acid loop in place of the GPNGF sequence of Loop 3.
Mutant 3-4A (RGD/RGD) exhibited a ,3-fold improvement in
binding compared to mutant 3-4C (RDG/RGD) to U87MG cells
(RGD/RGD: 562 nM versus RDG/RGD: 1563 nM), and at
least a 2-fold improvement in binding to K562-avb5 cells (RGD/
RGD: 761 nM versus RDG/RGD: 1365 nM); however, binding
to K562-avb3 cells was similar (RGD/RGD: 764 nM versus
RDG/RGD: 561 nM). Since U87MG cells express multiple
integrin receptors, including avb3 and avb5, the enhanced binding
of mutant 3-4A to these cells compared to mutant 3-4C most likely
results from the contributions of avb5 integrin. Despite the higher
affinity of mutant 3-4A to U87MG cells compared to EETI-II
2.5D, we did not observe an improvement in its ability to inhibit
cell adhesion to vitronectin (IC50:9 63 nM versus 1062 nM [8]).
In previous work, we established EETI-II 2.5D as a new agent
for non-invasive imaging of integrin expression in living subjects.
We showed that
18F- and
64Cu-labeled EETI-II 2.5D exhibited
high tumor uptake, and low uptake in non-target tissue, including
liver and kidneys [22,23].
64Cu-DOTA-knottin 3-4A exhibited
comparable tumor uptake levels to
64Cu-DOTA-knottin 2.5D in
U87MG xenograft models (3.5160.83%ID/g versus 4.476
1.21%ID/g at 1 h post injection from microPET data), in
accordance with their similar binding affinities. Radioactivity
clearance from the tumor site from 1 to 24 h post injection was
0.0760.02%ID/g/h for
64Cu-DOTA-knottin 3-4A, compared to
0.1360.04%ID/g/h for
64Cu-DOTA-knottin 2.5D. High tumor
uptake and rapid blood clearance led to favorable tumor-to-blood
(T/B) and tumor-to-muscle (T/M) ratios for both probes. At 4 h
post injection, the T/B and T/M ratios were 2763 and 3167,
respectively, for
64Cu-DOTA-knottin 3-4A, and 2563 (T/B) and
3061 (T/M) for
64Cu-DOTA-knottin 2.5D. Liver uptake was low,
with %ID/g values of ,1–2%ID/g. The primary clearance route
for
64Cu-DOTA-knottin 3-4A is the kidneys, with probe uptake
values ranging from ,8–12%ID/g at 124 h post-injection, and
decreasing to ,2–4%ID/g at 24 h. In comparison,
64Cu-DOTA-
knottin 2.5D exhibited lower kidney uptake values of ,3%ID/g at
4 post-injection, which were further reduced to ,1%ID/g at 24 h
post-injection [23]. Despite these differences, the tissue biodistibu-
tion of
64Cu-DOTA-knottin 3-4A is significantly improved
compared to other polypeptide-based probes, which often show
extremely high uptake and retention of
64Cu in the kidneys and
liver [34]. For example, in a recent study
64Cu-labeled tumor-
targeting peptides based on a scaffold from staphylococcal protein
A (affibodies) had kidney and liver uptake values ranging from 40–
240%ID/g and 5–12%ID/g, respectively, during measurements
taken over 20 h post injection [41].
In previous studies, we used a
64Cu-labeled EETI-II-based
knottin peptide containing a RDG sequence to measure non-
specific probe uptake in U87MG tumor xenograft models
(1.0960.48%ID/g and 0.7660.33%ID/g at 1 and 4 h post
injection, respectively) [23]. Target specificity of
64Cu-DOTA-
knottin 3-4A was measured by blocking experiments performed by
co-injecting an excess of unlabeled c(RGDyK) competitor (Figure 5
and Figure 6). In addition, decreases in tumor uptake with
64Cu-
DOTA-knottin 3-4A were seen at 1 h post injection
(0.8260.05%ID/g) in a MDA-MB-435 melanoma xenograft
model (data not shown), which expresses lower levels of avb3
integrin compared to U87MG xenograft tumors.
Myriad integrin-binding peptidomimetics containing a con-
strained RGD sequence have been developed as molecular imaging
agents [16,17,42,43]. Multivalent versions of these peptidomimetics
have been created with the goal of improving integrin binding
affinity and, hence, tumor uptake [44,45]. In one example,
c(RGDyK) dimers and higher order oligomers have been created
by chemical conjugation through addition of a glutamate branching
residue [46].Competitionbindingof
125I-echistatinto U87MGcells
with this dimeric ligand compared to monomeric c(RGDyK)
showed a small increase in binding affinity when two RGD motifs
were present (IC50=103614 nM versus 203632 nM). This 2-fold
difference in binding affinity to U87MG cells is similar to the
approximately 3-fold improvement we observed here with engi-
neered knottin peptides containing two RGD motifs compared to
one RGD motif (Table 1). In this previous study and in our current
work, molecules with two RGD motifs exhibited a free energy of
binding that was less than additive compared to the sum of
individual RGD monomer contributions, indicating that the RGD
motifs cannot both effectively engage integrin receptors due to steric
constraints, or that strain or distortion in the ligand or cell
membrane (i.e. to promote receptor conformation changes or
clustering) causes substantial entropy loss upon binding [47,48].
However, while we did not observe enhanced tumor uptake of
radiolabeled knottins containing two RGD motifs compared to one,
the
64Cu-labeled c(RGDyK) dimer was reported to exhibit a 2-fold-
increase in tumor uptake compared to monomeric
64Cu-labeled
c(RGDyK) [49,50].
In more recent examples, dimeric RGD-containing peptidomi-
metics with longer linkers have been created to increase the
flexibility between integrin binding motifs [45,51]. In one study, a
RGD dimer with a flexible glycine linker exhibited a 2-fold
increase in affinity compared to a RGD dimer without a flexible
linker (IC50=636nM versus 10265 nM, respectively) [52]. A
64Cu-labeled version of this dimer exhibited increased tumor
uptake in U87MG tumor-bearing mice compared to a dimer
without the linker (6.4361.22%ID/g versus 3.8360.22%ID/g,
respectively) [52]. Higher-order multivalent compounds, such as
RGD tetramers and octamers, have also exhibited higher binding
and greater effects on tumor uptake compared to dimeric
compounds [46,53], although liver and kidney uptake were also
increased.
64Cu-DOTA-knottin 3-4A showed moderate serum stability,
with ,30% of the intact probe remaining after 24 h. Intact probe
was excreted in the urine, but showed substantial degradation in
the tumor, liver, and kidneys at 1 h post injection. In contrast,
64Cu-DOTA-knottin 2.5D had much greater stability, with 82%
intact probe remaining after incubation in serum for 24 h, and
90% and 88% intact probe recovered from the tumor and kidneys,
respectively, at 1 h post injection [23]. The reduced stability of
64Cu-DOTA-knottin 3-4A compared to
64Cu-DOTA-knottin
2.5D is likely due to the replacement of a 5-amino acid loop
(GPNGF) with a 10-amino acid loop (REARGDMPRT), poten-
tially rendering the peptide more susceptible to cleavage with
proteases. We detected the presence of intact probe by radio-
HPLC as it is highly sensitive, and any unfolding or change in the
chemical nature of the knottin peptide would be readily evident in
the chromatograms. However functional read-outs of stability
would also be useful in future studies to determine if degradation
observed by reversed-phase HPLC correlates with functional
activity. Despite its higher binding affinity to U87MG cells, the
instability of
64Cu-DOTA-knottin 3-4A most likely influenced its
tissue biodistribution, and is one explanation for why enhanced
tumor uptake was not observed with this probe compared to
64Cu-
DOTA-knottin 2.5D. In future studies, alternative knottin mutants
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of amino acid sequence on serum and metabolic stability, or D-
amino acids could be explored in Loop 3 to improve its resistance
to proteases. However, many factors play a role in tumor uptake
and non-target tissue biodistribution of molecular imaging agents,
including blood clearance rate, probe stability and metabolism,
organ clearance route, tumor washout rate, receptor binding
affinity, and receptor binding specificity. For example, we and
others have shown a correlation between receptor binding affinity
and tumor uptake using polypeptide-based probes [23,54]. In
addition, a computational model was recently used to understand
and predict the interplay between molecular size, affinity, and
tumor uptake, and correlated with experimental observations from
the literature [55]. Using small peptidomimetics, correlations
between higher-order multivalency, receptor binding affinity, and
tumor uptake have also been uncovered [44,45]. In contrast,
recent studies have shown decreased tumor uptake with dimeric
polypeptides compared to their monomeric counterparts, perhaps
due to reduced tumor penetration and diffusion that occurs as
protein size increases [41,56,57]. In the future, protein engineering
will continue to generate additional tools to help illuminate the
contribution of size, chemical composition, binding affinity,
avidity, and stability to in vivo imaging performance, namely
pharmacokinetics and tissue biodistribution.
In summary, we further demonstrate the versatility of EETI-II as a
molecular scaffold for polypeptide engineering. To our knowledge,
this is the first example where two functional loops of a knottin
peptide have been engineered against an exogenous target. We
observed remarkable tolerance to loop length and sequence diversity
as the resulting 38 amino acid EETI-II mutant contained 21 non-
native amino acid residues distributed across two loops. While serum
and metabolic stability were reduced by these mutations, a
radiolabeled version of this knottin peptide exhibited favorable
properties for in vivo molecular imaging applications, namely high
target binding affinity, relatively high T/B and T/M ratios, and low
uptake and retention in non-target tissue. These results have
important implications for future polypeptide engineering efforts,
where multiple loops of a knottin peptide could be evolved to bind
with high affinity against a molecular target of interest.
Materials and Methods
Materials, Cell Lines, and Reagents
U87MGglioblastoma cellsand K562leukemiacellswere obtained
from American Type Culture Collection (Manassas, VA), and
integrin-transfected K562 cells [29] were provided by Scott Blystone
(SUNY Upstate Medical University). Detergent-solubilized avb3
integrin, octyl-beta-D-glucopyranoside formulation, was purchased
from Millipore (Billerica, MA).
125I-labeled echistatin and c(RGDyK)
were obtained from Amersham Biosciences (GE Healthcare, Piscat-
away, NJ), and Peptides International (Louisville, KY), respectively.
Phosphate buffered saline (PBS) was purchased from Invitrogen
(Carlsbad, CA). All other chemicals were obtained from Thermo
Fisher Scientific (Pittsburgh, PA) unless otherwise specified. Selective
SD-CAA media contained 20 g/L glucose, 6.7 g/L yeast nitrogen
base without amino acids, 5.4 g/L Bacto casamino acids. SG-CAA
media was identical except glucose was replaced by galactose.
Integrin binding buffer (IBB) was composed of 25 mM Tris pH 7.4,
150 mM NaCl, 2 mM CaCl2,1m MM g C l 2,1m MM n C l 2,a n d
0.1% bovine serum albumin (BSA).
Library Synthesis and Screening
The open reading frame encoding for EETI-II knottin 2.5D,
with the RGD motif scrambled to RDG, was generated by overlap
extension PCR. Loop 3 of this mutant (amino acids GPNGF) was
substituted with the sequences XXXRGDXXX, XXXRGD-
XXXX, and XXXRGDXXXXX, where X= any possible amino
acid, by overlap extension PCR (Table S1). Positions for rando-
mization were constructed using varying numbers of NNS
degenerate codons, where N=A, T, C, or G and S=C or G,
which codes for all possible 20 amino acids and the TAG stop
codon. The assembly PCR products were amplified using primers
with overlap to the pCT yeast display plasmid upstream or
downstream of the NheI and BamHI restriction sites, respectively
(Table S1). For each library, ,40 mg of DNA insert and 4 mgo f
linearized pCT vector were electroporated into the S. cerevisiae
strain EBY100 by homologous recombination as described [58].
The three libraries (,5–7610
6 transformants each) were com-
bined for a total potential diversity of ,2610
7 clones as estimated
by serial dilution plating and colony counting. Libraries were
grown in SD-CAA media and induced for yeast cell surface display
of knottin peptides in SG-CAA media as described [59].
For library screening, various concentrations of detergent-
solubilized avb3 integrin were added to yeast suspended in IBB for
2 h at room temperature. Next, a 1:250 dilution of chicken anti-
cMyc IgY antibody (Invitrogen) was added for 1 h at 4uC. The
cells were washed with ice-cold IBB and incubated with a 1:25
dilution of fluorescein-conjugated anti-av integrin antibody (mAb
13C2, Millipore) and a 1:100 dilution of Alexa 555-conjugated
goat anti-chicken IgG secondary antibody (Invitrogen) for 30 min
at 4uC. Cells were washed as above and avb3 integrin binders were
isolated using a Becton Dickinson FACSVantage SE instrument
(Stanford FACS facility). For the first round of sorting,
approximately 1610
8 yeast clones were analyzed for binding to
100 nM avb3 integrin. Collected yeast cells were cultured, induced
for expression, and sorted by subsequent rounds of FACS to
obtain an enriched population of integrin binders. To increase sort
stringency, integrin concentrations were successively decreased to
2 nM in later sort rounds, and a diagonal sort gate was used to
isolate yeast cells with enhanced integrin binding (FITC
fluorescence) for a given protein expression level (Alexa 555
fluorescence). In between sorting rounds, cells were analyzed by
dual-color flow cytometry using a BD FACSCalibur and
CellQuest software (Becton Dickinson). Finally, an ‘‘off-rate’’ sort
was performed by incubating yeast with 2 nM avb3 integrin,
followed by a 4 h unbinding step performed in the presence of
125 nM EETI-II knottin 2.5D competitor. A summary of the
library sorting details is presented in Table S2. Plasmid DNA was
recovered using a Zymoprep kit (Zymo Research Corporation,
Orange, CA), amplified in XL-1 blue supercompetent E. coli cells
(Stratagene/Agilent Technologies, Santa Clara, CA) and se-
quenced (MCLAB, South San Francisco, CA).
Knottin Peptide Synthesis and Folding
Knottin peptides were synthesized on a CS Bio CS336
instrument using Fmoc-based solid phase peptide synthesis with
Rink amide resin (CS Bio Company). Fmoc groups were removed
with 20% piperidine in N,N-dimethylformamide (DMF). Amino
acid coupling was performed using HOBt/diisopropylcarbodii-
mide chemistry in DMF. After synthesis, side-chain deprotection
and resin cleavage was achieved by addition of a 94:2.5:2.5:1 (v/v)
mixture of trifluoroacetic acid (TFA)/triisopropylsilane/ethane-
dithiol/water for 2 h at room temperature. The crude product was
precipitated with cold anhydrous diethyl ether, and purified by
reversed-phase HPLC using a Varian Prostar instrument and
Vydac C18 columns. Linear gradients of 90% acetonitrile in water
containing 0.1% (v/v) TFA were used for all peptide purifications,
which were monitored at an absorbance of 220 nm. Peptide purity
Engineering Multiple Loops in EETI-II
PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e16112was analyzed by analytical scale reversed-phase HPLC using a
Vydac C18 column. Molecular masses were determined by matrix-
assisted laser desorption/ionization time-of-flight mass spectrom-
etry (MALDI-TOF MS) on a Perseptive Voyager-DE-RP
Biospectrometry instrument (Stanford Protein and Nucleic Acid
facility) (Figure S1 and Table S3). Folding reactions were
performed by incubating peptides with 2.5 mM reduced glutathi-
one and 20% dimethlysulfoxide (v/v) in 0.1 M ammonium
bicarbonate, pH 9 with gentle rocking overnight. The final
oxidized product was purified by reversed-phase HPLC as
described above and lyophilized. Purified peptides were dissolved
in water, and concentrations were determined by amino acid
analysis (AAA Service Laboratory, Damascus, OR). Peptide purity
and molecular masses were determined by analytical scale
reversed-phase HPLC and MALDI-TOF MS (Figure S1 and
Table S3). Purity was determined to be greater than 95%.
Cell Surface Competition Binding Assay
Competition binding assays were performed as previously
described [33,60] to measure the relative binding affinities of
engineered knottin peptides and echistatin. Briefly, 2610
5
U87MG or K562 cells were incubated with 0.06 nM
125I-labeled
echistatin and varying concentrations of peptides in IBB at room
temperature for 3 h. The cell-bound radioactivity remaining after
washing was determined by gamma-counting. Half-maximal
inhibitory concentration (IC50) values were determined by non-
linear regression analysis using KaleidaGraph software (Synergy
Software), and are presented as the average of experiments
performed on three separate days.
Cell Adhesion Assay
Cell adhesion assays were performed using Cytomax fibronec-
tin- and vitronectin-coated strips (Millipore) as previously
described [8,61] and according to the manufacturer’s protocol.
Briefly, coated strips were rehydrated with PBS. Varying
concentrations of peptides were added to 10
5 U87MG cells in
100 mL of IBB, incubated for 2 h at 37uC, 5% CO2, and washed
with Dulbecco’s PBS (DPBS, Invitrogen). Remaining adherent
cells were incubated with 100 mL of 0.2% crystal violet and 10%
ethanol for 5 min at room temperature, washed in DPBS and
solubilized with 100 mL/well of a 50:50 mixture of 100 mM
sodium phosphate, pH 4.5 and ethanol for 5 min. The absorbance
at 600 nm was measured using a SPECTRAmax PLUS
(Molecular Devices) microtiter plate reader. IC50 values were
determined by non-linear regression analysis using KaleidaGraph
software, and are the average of experiments performed on three
separate days. Data was normalized against samples containing no
competing peptide and background signal from uncoated wells.
Chemical Conjugation of DOTA and
64Cu Radiolabeling
Knottin peptides were reacted with a 5-fold molar excess of N-
hydroxysuccinimide ester-activated DOTA (DOTA-NHS ester;
Macrocyclics, Dallas, TX) in DMF containing 2% N,N-diisopro-
pylethylamine for 0.5 h to yield DOTA-knottin 3-4A. The
DOTA-conjugated knottin peptide was purified by reversed-phase
HPLC. Molecular masses were determined by MALDI-TOF MS
and peptide products were analyzed by analytical scale reversed-
phase HPLC (Figure S1 and Table S3). For each radiolabeling
reaction, approximately 10–25 mg of DOTA-knottin 3-4A was
incubated with 1–2 mCi
64CuCl2 (University of Wisconsin-
Madison, Madison, WI) in 0.1 N sodium acetate (pH=6) for
1 h at 42uC. The radiolabeled peptide was purified using a PD-10
column (Amersham Biosciences/GE Healthcare), eluted with PBS
(pH 7.4), and passed through a 0.22 mm filter for animal
experiments. The radiochemical purity, determined as the ratio
of the main product peak to other peaks, was determined by
HPLC to be .95%. The radiochemical yield, determined as the
ratio of final activity of the product over the starting activity used
for the reaction, was usually over 80%. The specific activity of the
probe was ,500 Ci/mmol.
Tumor Model
Animal procedures were carried out according to a protocol
approved by Stanford University Administrative Panels on
Laboratory Animal Care (APLAC Protocol 11580). U87MG
glioblastoma cells were maintained at 37uC/5% CO2 in
Dulbecco’s Modified Eagle Medium, 10% heat-inactivated fetal
bovine serum, and penicillin-streptomycin (all from Invitrogen).
Female athymic nude mice (nu/nu), obtained at 4–6 weeks of age
(Charles River Laboratories, Inc., Wilmington, MA), were injected
subcutaneously in the right or left shoulder with ,10
7 U87MG
cells suspended in 100 mL of PBS. Mice were used for in vivo
imaging studies when their tumors reached approximately 10
millimeters in diameter.
MicroPET Imaging of Tumor Xenografts
U87MG tumor-bearing mice (n=3 or more for each probe)
were injected with ,100 mCi (,0.5 nmol) of probe via the tail vein
and imaged with a microPET R4 rodent model scanner (Siemens
Medical, Knoxville, TN) using 5 min static scans. Images were
reconstructed by a two-dimensional ordered expectation maxi-
mum subset algorithm and calibrated as previously described [53].
ROIs were drawn over the tumor on decay-corrected whole body
images using ASIPro VM software (Siemens Medical). ROIs were
converted to counts/g/min, and %ID/g values were determined
assuming a tissue density of 1 g/mL. No attenuation correction
was performed. For the blocking experiments, mice were co-
injected with 330 mg( ,0.5 mmol) of unlabeled c(RGDyK), a
pentapeptide that binds to avb3 and avb5 integrins [8,62] at a
similar receptor binding site as the engineered knottin peptides.
In Vivo Biodistribution Studies
Anesthetized nude mice bearing U87MG tumor xenografts
were injected with ,50–100 mCi (,0.25–0.5 nmol) of
64Cu-
DOTA-knottin 3-4A via the tail vein, and were euthanized at 1, 4,
and 24 h post injection. Blood, bone, brain, heart, kidney, liver,
lung, muscle, pancreas, skin, spleen, and tumor tissue were
removed and weighed, and their radioactivity levels (counts per
minute) were measured by gamma counting. The radioactivity
uptake in the tumor and normal tissue was reported as the percent
injected dose per gram (%ID/g) of tissue and represent the mean
and standard deviation of experiments performed on three mice.
For each mouse, the activity of tissue samples was calibrated
against a pre-measured aliquot of the radiotracer and normalized
to the whole bodyweight and to the residual radioactivity present
in the tail. To test integrin-targeting specificity, U87MG tumor-
bearing mice (n=3) were co-injected with
64Cu-DOTA-knottin 3-
4A and 330 mg( ,0.5 mmol) of unlabeled c(RGDyK), and
biodistribution of the radiolabeled peptide was determined 1 h
after injection.
In Vitro and In Vivo Stability
Aliquots containing up to 400 mCi of
64Cu-DOTA-knottin 3-4A
were incubated in 50% mouse serum for up to 24 h. At various
time points, samples were mixed with an equal volume of 99.9%
water/0.1% TFA, further acidified with ,1% (v/v) TFA, and
centrifuged to remove precipitants. Soluble fractions were filtered
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and analyzed by reversed-phase radio-HPLC using a Vydac C18
column. For metabolic stability analysis, anesthetized nude mice
bearing U87MG tumor xenografts were injected with 200–
400 mCi of
64Cu-DOTA-knottin 3-4A via the tail vein, and were
euthanized at 1 h post injection. Tumor, kidney, and liver tissues
were homogenized with a mortar/pestle in 1 ml DMF. The lysates
were acidified, centrifuged, and filtered using a 0.2 mm Costar
Spin-X microcentrifuge filter to isolate soluble metabolites.
Filtrates were injected onto a Vydac C18 column and analyzed
by reversed-phase HPLC. Fractions were collected every 1 min
and analyzed by gamma counting to determine the counts per
minute (cpm). Urine samples were collected 1 h post injection and
were also analyzed by radio-HPLC. The intact radiotracer elutes
at approximately 15 min, and the major hydrophilic metabolites
and free copper elute with the column dead volume.
Statistical Analysis
All data are presented as the average value 6 the SD of at least
3 independent measurements. Statistical analysis for animal
studies and binding studies were performed by two factor ANOVA
without replication analysis using Microsoft Excel. Significance
was assigned for p values of ,0.05.
Supporting Information
Table S1 Primers for library construction. Primers for PCR
assembly of EETI-II libraries, and primers for amplification of
assembly products and homologous recombination in yeast.
(DOCX)
Table S2 Library screening details. Nine sort rounds were
performed against varying concentrations of avb3 integrin. In
round 9, an ‘‘off-rate’’ sort was performed by incubating yeast with
2n Mavb3 integrin, followed by a 4 h unbinding step in the
presence of 125 nM EETI-II knottin 2.5D competitor.
(DOCX)
Table S3 Mass spectrometry. MALDI-TOF-MS of the reduced,
oxidized (folded), or DOTA conjugated form of knottin peptide 3-
4A. The [M+H]
+ state is indicated.
(DOCX)
Figure S1 Reversed-phase HPLC chromatograms of knottin
synthesis, folding, and DOTA conjugation. Representative
analytical scale HPLC traces of knottin 3-4A, indicated by
asterisks. (A) Crude material from peptide synthesis, (B) Folding
reaction, (C) Purified oxidized (folded) peptide, and (D) Purified
DOTA conjugated peptide. (A) Gradient =20–50% solvent B
(90% acetonitrile/10% water/0.1% trifluoroacetic acid) over
30 min, and (B–D) Gradient =10–50% solvent B over 30 min.
(TIF)
Figure S2 Competition binding to integrin receptors expressed
on K562 cell lines. Varying concentrations of unlabeled peptides
were incubated with
125I-echistatin and allowed to compete for
binding to cell surface receptors present on (A) untransfected K562
cells, which express a5b1 integrin, or K562 cells stably transfected
with (B) avb3 integrin, (C) avb5 integrin, or (D) aiibb3 integrin.
Percent of
125I-echistatin bound to the cell surface is plotted versus
the concentration of unlabeled echistatin (N), knottin 3-4A (X), or
knottin 3-4C (&). Data shown are the average of three replicates
performed on different days and error bars represent standard
deviations. IC50 values are summarized in Table 1.
(TIF)
Figure S3 Cell binding and uptake assay. To measure cell
binding and uptake, 5610
5 U87MG cells were suspended in
50 mL IBB and incubated with
64Cu-DOTA-knottin 3-4A
(1.5 mCi/tube in 100 mL IBB) at 37uC for 30, 60, and 120 min.
Cells were washed three times with ice-cold PBS and pelleted by
centrifugation. The radioactivity of the cell pellet was measured
with a gamma counter (PerkinElmer 1470, Waltham, MA). Cell
binding and uptake of
64Cu-DOTA-knottin 3-4A was expressed as
the percentage of added radioactivity. Target specificity was
further determined by blocking experiments where 1 mg unlabeled
c(RGDyK) pentapeptide was co-incubated with
64Cu-DOTA-
knottin 3-4A (block). Experiments were performed in triplicate.
(TIF)
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